Science
Antibody advantage: Precision targeting of cancer cells
We are developing an antibody-based technology that targets a unique protein marker common on tumor cells but rare in healthy tissue. Our Antibody Drug Conjugate (ADC) platform is designed to deliver potent cancer-killing drugs with precision. By combining engineered antibodies with our proprietary stable linker and tailored payloads, our technology remains stable in the bloodstream and ensures controlled payload release only once inside tumor cells. This platform is built to address multiple aggressive cancers that currently lack effective therapies, enabling targeted treatment where it’s needed most.
Compare systemic chemotherapy exposure with the targeted delivery of Antigenix ADCs.
Patented design
Our patented antibody can serve as the foundation for multiple precision therapy formats. By pairing the same targeting antibody with different types of treatment, we can attack cancer through multiple mechanisms. This flexibility allows us to build a diverse pipeline from a single innovation.
ADCs Explained
Redefining cancer therapy through precision targeting
Antibody–drug conjugates (ADCs) are a class of precision therapeutics reshaping the future of cancer treatment. Unlike chemotherapy, ADCs are designed to selectively target and kill tumor cells while sparing healthy tissue.
How ADCs work
